ImmVira
OverviewSuggest Edit
ImmVira is a company that develops biopharmaceutical technology in the field of immunotherapy. The company provides medical solutions to treat cancer and tumor. It offers a product called Oncolytic Herpes Simplex Virus that aims to eliminate metastatic tumors or tumors inaccessible by direct injection.
| Type | Private | |
| Founded | 2015 | |
| HQ | Shenzhen Shi, CN | Map |
| Website | immvira-theravir.com |
Recent NewsAll News
- ImmVira Launches Pilot-scale Production Line to Expedite the Advancement of Next-generation OV Clinical Trials
- ImmVira completed the first dosing for Phase II of MVR-T3011 (intratumoral injection) in the U.S. and China
- ImmVira will present the U.S. Clinical Phase I Study Results of MVR-T3011 via Intratumoral Administration at ASCO 2021
- ImmVira Announces Preclinical and Clinical Data to Be Presented at the 2021 ASCO and AACR Annual Meeting
Latest Updates
| Employees (est.) (Apr 2022) | 11 | (-8%) |
| Cybersecurity rating | C | More |
Key People/Management at ImmVira
Grace Zhou
CEO/CSO
Bernard Roizman
Chair of BOD
ImmVira Office Locations
ImmVira has an office in Shenzhen Shi
Shenzhen Shi, CN (HQ)
1301 Guanguang Rd, Longhua Qu
ImmVira Financials and Metrics
Summary Metrics
Founding Date | 2015 |
ImmVira total Funding | $90.5 m |
ImmVira latest funding size | $10 m |
Time since last funding | 2 years ago |
ImmVira investors | MF Capital, Apricot Capital, Huagai Capital, Yonghua Capital, TriWise Capital, Leaguer Group, Cowin Capital, BOHE Angel Fund, Huiying Taifu Investment, Shanghai Healthcare Capital |
ImmVira's latest funding round in September 2020 was reported to be $10 m. In total, ImmVira has raised $90.5 m
ImmVira Cybersecurity Score
ImmVira Online and Social Media Presence
ImmVira's Trends
ImmVira News and Updates
July 19, 2021
ImmVira Launches Pilot-scale Production Line to Expedite the Advancement of Next-generation OV Clinical Trials
SHENZHEN, China, July 18, 2021 /PRNewswire/ -- On July 18, 2021, ImmVira inaugurated a pilot-scale production line in Shenzhen and officially initiated its in-house production of our next-generation oncolytic viruses (OV) used for IND applications and Phase I/II clinical trials....
June 12, 2021
ImmVira completed the first dosing for Phase II of MVR-T3011 (intratumoral injection) in the U.S. and China
SHENZHEN, China, June 11, 2021 /PRNewswire/ -- ImmVira announced that in the Phase II Clinical Trials of its leading oncolytic virus product, MVR-T3011* as intratumoral administration (MVR-T3011 IT), ImmVira has completed the first dosing in both China and the U.S. on May 28 2021 and June...
June 02, 2021
ImmVira will present the U.S. Clinical Phase I Study Results of MVR-T3011 via Intratumoral Administration at ASCO 2021
SHENZHEN, China, June 2, 2021 /PRNewswire/ -- ImmVira will present results from its clinical Phase I study of MVR-T3011 via intratumoral (IT) administration at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4-8, 2021 for the first time. MVR-T3011 is ImmVira's...
April 08, 2021
ImmVira Announces Preclinical and Clinical Data to Be Presented at the 2021 ASCO and AACR Annual Meeting
SHENZHEN, China, April 8, 2021 /PRNewswire/ -- ImmVira today announces that the company will be presenting its first innovative product, MVR-T3011, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4-8 2021. Results from the first Phase 1 study of MVR-T3011...
December 31, 2020
ImmVira Announces Series C Financing with Leading Specialist Investors
SHENZHEN, China, Dec. 31, 2020 /PRNewswire/ -- ImmVira Group Company ("the Company"), a biotechnology platform dedicated to the development of oncolytic virus("OV") and vector type approaches to create more effective and safer therapies against cancer, announced today the signing of...
July 01, 2020
Immvira Announces the Appointment of Carl Yeung as Chief Financial Officer
SHENZHEN, China, June 30, 2020 /PRNewswire/ -- Today Immvira Group Company (Immvira or the "Company"), a biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics, announces the appointment of Carl Yeung as Chief Financial...
ImmVira Frequently Asked Questions
When was ImmVira founded?
ImmVira was founded in 2015.
Who are ImmVira key executives?
ImmVira's key executives are Grace Zhou and Bernard Roizman.
How many employees does ImmVira have?
ImmVira has 11 employees.
Who are ImmVira competitors?
Competitors of ImmVira include ImmunSYS, Precision Medicines and Plus Therapeutics.
Where is ImmVira headquarters?
ImmVira headquarters is located at 1301 Guanguang Rd, Longhua Qu, Shenzhen Shi.
Where are ImmVira offices?
ImmVira has an office in Shenzhen Shi.
How many offices does ImmVira have?
ImmVira has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies